Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sendi...
Compass Pathways reported a second pivotal phase 3 success for its psilocybin therapy in treatment-resistant depression, boosting its shares roughly 30% and setting up plans to seek regulatory approval.
Why it mattersPhase 3 psilocybin win for treatment-resistant depression should prompt investors to accelerate regulatory filing and valuation updates.